The Sinopharm COVID-19 vaccine has been licensed for emergency use in children over the age of three in China, according to a statement from the pharmaceutical giant’s subsidiary.
“On July 16, the inactivated COVID-19 vaccine developed by the Beijing Institute of Biological Products [part of Sinopharm] gained emergency use permission in persons aged 3 to 17,” the China National Biotec Group Company Limited announced.
According to the statement, testing showed that the vaccination was safe, with no significant adverse effects other than a temperature and slight discomfort in the injection site.
On May 7, the World Health Organization authorized China’s Sinopharm vaccine for emergency use.
On December 30, 2020, the Beijing Institute of Biological Products announced that the vaccination is 79.34 percent effective.